글로벌 항구토제 시장 2023-2027 : 화학요법, 외과적 치료, 위장염, 기타

■ 영문 제목 : Global Antiemetic Drug Market 2023-2027

Technavio가 발행한 조사보고서이며, 코드는 IRTNTR75902-23 입니다.■ 상품코드 : IRTNTR75902-23
■ 조사/발행회사 : Technavio
■ 발행일 : 2023년 7월
■ 페이지수 : 약120
■ 작성언어 : 영문
■ 보고서 형태 : PDF
■ 납품 방식 : E메일 (주문후 24시간내)
■ 조사대상 지역 : 글로벌
■ 산업 분야 : 의약품
■ 판매가격 / 옵션 (부가세 10% 별도)
Single User (1인 열람용)USD2,500 ⇒환산₩3,375,000견적의뢰/주문/질문
Enterprise License (기업 열람용)USD4,000 ⇒환산₩5,400,000견적의뢰/주문/질문
가격옵션 설명
- 납기는 즉일~2일소요됩니다. 3일이상 소요되는 경우는 별도표기 또는 연락드립니다.
- 지불방법은 계좌이체/무통장입금 또는 카드결제입니다.
글로벌 항구토제 시장 2023-2027
항구토제 시장은 2022년에서 2027년까지 16억 3,281만 달러 규모로 성장할 것으로 예상되며, 예측 기간 동안 6.47%의 CAGR을 기록할 것으로 예상됩니다. 이 보고서는 항구토제 시장에 대한 전반적인 분석, 시장 규모와 예측, 동향, 성장 촉진요인, 과제, 약 25개 벤더에 대한 벤더 분석 등의 정보를 담고 있습니다.
현재 시장 시나리오, 최신 동향 및 촉진 요인, 전체 시장 환경에 대한 최신 분석을 제공합니다. 이 시장은 전 세계 노인 인구의 증가, 메스꺼움과 구토의 유병률 증가, 의료비 증가가 시장을 주도하고 있습니다.

Technavio사의 항구토제 시장은 다음과 같이 세분화되어 있습니다.

용도별
- 화학요법
- 외과적 치료
- 위장염
- 기타

약효군별
- 5-Hydroxytryptamine 3(5-HT 3) 수용체 길항제
- 도파민 길항제
- 뉴로키닌-1 (NK 1) 수용체 길항제
- 칸나비노이드 수용체 길항제
- 기타

지역별
- 북미
- 유럽
- 아시아
- 기타 지역(ROW)

이 보고서는 항구토제 관리에서 디지털 헬스 솔루션의 통합이 향후 몇 년 동안 항구토제 시장의 성장을 촉진하는 주요 이유 중 하나로 꼽고 있습니다. 또한, 최근 항구토제 관련 개발이 증가하고 신흥국에서 항구토제에 대한 수요가 증가함에 따라 시장 수요가 크게 늘어날 것으로 예상하고 있습니다.

본 보고서는 항구토제 시장에 대해 다음과 같은 분야를 다루고 있습니다.
- 항구토제 시장 규모
- 항구토제 시장 예측
- 항구토제 시장의 산업 분석

이 보고서는 항구토제 시장의 주요 벤더인 Algen Healthcare Ltd., Boehringer Ingelheim International GmbH, Bristol Laboratories Ltd., Cadila Pharmaceuticals Ltd., Cipla Ltd., Eagle Pharmaceuticals Inc., Fresenius SE and Co. KGaA, GlaxoSmithKline Plc, Helsinn Healthcare SA, Heron Therapeutics Inc., Lupin Ltd., Merck and Co. Inc., Novartis AG, Otsuka Holdings Co. Ltd., Pfizer Inc., RedHill Biopharma Ltd., Sanofi, Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., 및 Viatris Inc. 등의 기업 정보를 분석하고 있습니다. 또한, 항구토제 시장 분석 보고서에는 시장 성장에 영향을 미치는 향후 동향과 과제에 대한 정보도 포함되어 있습니다. 이는 기업이 전략을 수립하고 다가오는 모든 성장 기회를 활용하는 데 도움이 될 것으로 예상되고 있습니다.

이 연구는 업계 주요 참여자들의 의견을 포함하여 1차 및 2차 정보를 객관적으로 결합하여 수행되었습니다. 이 보고서는 주요 벤더에 대한 분석과 함께 포괄적인 시장 및 벤더 현황을 제공합니다.

이 보고서는 이익, 가격, 경쟁, 프로모션 등 주요 매개변수를 분석하여 여러 출처의 데이터를 조사, 통합, 요약하는 방식으로 시장의 상세한 모습을 제시합니다. 또한, 주요 산업 영향력자를 식별하여 시장의 다양한 측면을 제시합니다. 제시된 데이터는 포괄적이고 신뢰할 수 있는 1차 및 2차에 걸친 광범위한 조사 결과입니다. 시장 조사 보고서는 정확한 시장 성장을 예측하기 위해 완전한 경쟁 환경과 정성적 및 정량적 조사를 통한 면밀한 공급업체 선정 방법 및 분석을 제공합니다.
■ 보고서 개요

1. 개요
2. 세계의 항구토제 시장 현황
3. 세계의 항구토제 시장 규모
4. 과거 시장 규모
5. 파이브 포스 분석
6. 약효별 시장 분석
7. 용도별 시장 분석
8. 고객 현황
9. 지역별 분석
10. 추진 요인/과제/동향
11. 기업 현황
12. 기업 분석
13. 부록

■ 보고서 목차

1 Executive Summary
o 1.1 Market overview
o Exhibit 01: Executive Summary – Chart on Market Overview
o Exhibit 02: Executive Summary – Data Table on Market Overview
o Exhibit 03: Executive Summary – Chart on Global Market Characteristics
o Exhibit 04: Executive Summary – Chart on Market By Geographical Landscape
o Exhibit 05: Executive Summary – Chart on Market Segmentation by Drug Class
o Exhibit 06: Executive Summary – Chart on Market Segmentation by Application
o Exhibit 07: Executive Summary – Chart on Incremental Growth
o Exhibit 08: Executive Summary – Data Table on Incremental Growth
o Exhibit 09: Executive Summary – Chart on Vendor Market Positioning
2 Market Landscape
o 2.1 Market ecosystem
o Exhibit 10: Parent market
o Exhibit 11: Market Characteristics
3 Market Sizing
o 3.1 Market definition
o Exhibit 12: Offerings of vendors included in the market definition
o 3.2 Market segment analysis
o Exhibit 13: Market segments
o 3.3 Market size 2022
o 3.4 Market outlook: Forecast for 2022-2027
o Exhibit 14: Chart on Global – Market size and forecast 2022-2027 ($ million)
o Exhibit 15: Data Table on Global – Market size and forecast 2022-2027 ($ million)
o Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
o Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
4 Historic Market Size
o 4.1 Global antiemetic drug market 2017 – 2021
o Exhibit 18: Historic Market Size – Data Table on global antiemetic drug market 2017 – 2021 ($ million)
o 4.2 Drug Class Segment Analysis 2017 – 2021
o Exhibit 19: Historic Market Size – Drug Class Segment 2017 – 2021 ($ million)
o 4.3 Application Segment Analysis 2017 – 2021
o Exhibit 20: Historic Market Size – Application Segment 2017 – 2021 ($ million)
o 4.4 Geography Segment Analysis 2017 – 2021
o Exhibit 21: Historic Market Size – Geography Segment 2017 – 2021 ($ million)
o 4.5 Country Segment Analysis 2017 – 2021
o Exhibit 22: Historic Market Size – Country Segment 2017 – 2021 ($ million)
5 Five Forces Analysis
o 5.1 Five forces summary
o Exhibit 23: Five forces analysis – Comparison between 2022 and 2027
o 5.2 Bargaining power of buyers
o Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027
o 5.3 Bargaining power of suppliers
o Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027
o 5.4 Threat of new entrants
o Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027
o 5.5 Threat of substitutes
o Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027
o 5.6 Threat of rivalry
o Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027
o 5.7 Market condition
o Exhibit 29: Chart on Market condition – Five forces 2022 and 2027
6 Market Segmentation by Drug Class
o 6.1 Market segments
o Exhibit 30: Chart on Drug Class – Market share 2022-2027 (%)
o Exhibit 31: Data Table on Drug Class – Market share 2022-2027 (%)
o 6.2 Comparison by Drug Class
o Exhibit 32: Chart on Comparison by Drug Class
o Exhibit 33: Data Table on Comparison by Drug Class
o 6.3 5-Hydroxytryptamine 3 (5-HT 3) receptor antagonist – Market size and forecast 2022-2027
o Exhibit 34: Chart on 5-Hydroxytryptamine 3 (5-HT 3) receptor antagonist – Market size and forecast 2022-2027 ($ million)
o Exhibit 35: Data Table on 5-Hydroxytryptamine 3 (5-HT 3) receptor antagonist – Market size and forecast 2022-2027 ($ million)
o Exhibit 36: Chart on 5-Hydroxytryptamine 3 (5-HT 3) receptor antagonist – Year-over-year growth 2022-2027 (%)
o Exhibit 37: Data Table on 5-Hydroxytryptamine 3 (5-HT 3) receptor antagonist – Year-over-year growth 2022-2027 (%)
o 6.4 Dopamine antagonist – Market size and forecast 2022-2027
o Exhibit 38: Chart on Dopamine antagonist – Market size and forecast 2022-2027 ($ million)
o Exhibit 39: Data Table on Dopamine antagonist – Market size and forecast 2022-2027 ($ million)
o Exhibit 40: Chart on Dopamine antagonist – Year-over-year growth 2022-2027 (%)
o Exhibit 41: Data Table on Dopamine antagonist – Year-over-year growth 2022-2027 (%)
o 6.5 Neurokinin-1 (NK 1) receptor antagonist – Market size and forecast 2022-2027
o Exhibit 42: Chart on Neurokinin-1 (NK 1) receptor antagonist – Market size and forecast 2022-2027 ($ million)
o Exhibit 43: Data Table on Neurokinin-1 (NK 1) receptor antagonist – Market size and forecast 2022-2027 ($ million)
o Exhibit 44: Chart on Neurokinin-1 (NK 1) receptor antagonist – Year-over-year growth 2022-2027 (%)
o Exhibit 45: Data Table on Neurokinin-1 (NK 1) receptor antagonist – Year-over-year growth 2022-2027 (%)
o 6.6 Cannabinoid receptor antagonist – Market size and forecast 2022-2027
o Exhibit 46: Chart on Cannabinoid receptor antagonist – Market size and forecast 2022-2027 ($ million)
o Exhibit 47: Data Table on Cannabinoid receptor antagonist – Market size and forecast 2022-2027 ($ million)
o Exhibit 48: Chart on Cannabinoid receptor antagonist – Year-over-year growth 2022-2027 (%)
o Exhibit 49: Data Table on Cannabinoid receptor antagonist – Year-over-year growth 2022-2027 (%)
o 6.7 Others – Market size and forecast 2022-2027
o Exhibit 50: Chart on Others – Market size and forecast 2022-2027 ($ million)
o Exhibit 51: Data Table on Others – Market size and forecast 2022-2027 ($ million)
o Exhibit 52: Chart on Others – Year-over-year growth 2022-2027 (%)
o Exhibit 53: Data Table on Others – Year-over-year growth 2022-2027 (%)
o 6.8 Market opportunity by Drug Class
o Exhibit 54: Market opportunity by Drug Class ($ million)
o Exhibit 55: Data Table on Market opportunity by Drug Class ($ million)
7 Market Segmentation by Application
o 7.1 Market segments
o Exhibit 56: Chart on Application – Market share 2022-2027 (%)
o Exhibit 57: Data Table on Application – Market share 2022-2027 (%)
o 7.2 Comparison by Application
o Exhibit 58: Chart on Comparison by Application
o Exhibit 59: Data Table on Comparison by Application
o 7.3 Chemotherapy – Market size and forecast 2022-2027
o Exhibit 60: Chart on Chemotherapy – Market size and forecast 2022-2027 ($ million)
o Exhibit 61: Data Table on Chemotherapy – Market size and forecast 2022-2027 ($ million)
o Exhibit 62: Chart on Chemotherapy – Year-over-year growth 2022-2027 (%)
o Exhibit 63: Data Table on Chemotherapy – Year-over-year growth 2022-2027 (%)
o 7.4 Surgery – Market size and forecast 2022-2027
o Exhibit 64: Chart on Surgery – Market size and forecast 2022-2027 ($ million)
o Exhibit 65: Data Table on Surgery – Market size and forecast 2022-2027 ($ million)
o Exhibit 66: Chart on Surgery – Year-over-year growth 2022-2027 (%)
o Exhibit 67: Data Table on Surgery – Year-over-year growth 2022-2027 (%)
o 7.5 Gastroenteritis – Market size and forecast 2022-2027
o Exhibit 68: Chart on Gastroenteritis – Market size and forecast 2022-2027 ($ million)
o Exhibit 69: Data Table on Gastroenteritis – Market size and forecast 2022-2027 ($ million)
o Exhibit 70: Chart on Gastroenteritis – Year-over-year growth 2022-2027 (%)
o Exhibit 71: Data Table on Gastroenteritis – Year-over-year growth 2022-2027 (%)
o 7.6 Others – Market size and forecast 2022-2027
o Exhibit 72: Chart on Others – Market size and forecast 2022-2027 ($ million)
o Exhibit 73: Data Table on Others – Market size and forecast 2022-2027 ($ million)
o Exhibit 74: Chart on Others – Year-over-year growth 2022-2027 (%)
o Exhibit 75: Data Table on Others – Year-over-year growth 2022-2027 (%)
o 7.7 Market opportunity by Application
o Exhibit 76: Market opportunity by Application ($ million)
o Exhibit 77: Data Table on Market opportunity by Application ($ million)
8 Customer Landscape
o 8.1 Customer landscape overview
o Exhibit 78: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
9 Geographic Landscape
o 9.1 Geographic segmentation
o Exhibit 79: Chart on Market share By Geographical Landscape 2022-2027 (%)
o Exhibit 80: Data Table on Market share By Geographical Landscape 2022-2027 (%)
o 9.2 Geographic comparison
o Exhibit 81: Chart on Geographic comparison
o Exhibit 82: Data Table on Geographic comparison
o 9.3 North America – Market size and forecast 2022-2027
o Exhibit 83: Chart on North America – Market size and forecast 2022-2027 ($ million)
o Exhibit 84: Data Table on North America – Market size and forecast 2022-2027 ($ million)
o Exhibit 85: Chart on North America – Year-over-year growth 2022-2027 (%)
o Exhibit 86: Data Table on North America – Year-over-year growth 2022-2027 (%)
o 9.4 Europe – Market size and forecast 2022-2027
o Exhibit 87: Chart on Europe – Market size and forecast 2022-2027 ($ million)
o Exhibit 88: Data Table on Europe – Market size and forecast 2022-2027 ($ million)
o Exhibit 89: Chart on Europe – Year-over-year growth 2022-2027 (%)
o Exhibit 90: Data Table on Europe – Year-over-year growth 2022-2027 (%)
o 9.5 Asia – Market size and forecast 2022-2027
o Exhibit 91: Chart on Asia – Market size and forecast 2022-2027 ($ million)
o Exhibit 92: Data Table on Asia – Market size and forecast 2022-2027 ($ million)
o Exhibit 93: Chart on Asia – Year-over-year growth 2022-2027 (%)
o Exhibit 94: Data Table on Asia – Year-over-year growth 2022-2027 (%)
o 9.6 Rest of World (ROW) – Market size and forecast 2022-2027
o Exhibit 95: Chart on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
o Exhibit 96: Data Table on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
o Exhibit 97: Chart on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
o Exhibit 98: Data Table on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
o 9.7 US – Market size and forecast 2022-2027
o Exhibit 99: Chart on US – Market size and forecast 2022-2027 ($ million)
o Exhibit 100: Data Table on US – Market size and forecast 2022-2027 ($ million)
o Exhibit 101: Chart on US – Year-over-year growth 2022-2027 (%)
o Exhibit 102: Data Table on US – Year-over-year growth 2022-2027 (%)
o 9.8 China – Market size and forecast 2022-2027
o Exhibit 103: Chart on China – Market size and forecast 2022-2027 ($ million)
o Exhibit 104: Data Table on China – Market size and forecast 2022-2027 ($ million)
o Exhibit 105: Chart on China – Year-over-year growth 2022-2027 (%)
o Exhibit 106: Data Table on China – Year-over-year growth 2022-2027 (%)
o 9.9 Germany – Market size and forecast 2022-2027
o Exhibit 107: Chart on Germany – Market size and forecast 2022-2027 ($ million)
o Exhibit 108: Data Table on Germany – Market size and forecast 2022-2027 ($ million)
o Exhibit 109: Chart on Germany – Year-over-year growth 2022-2027 (%)
o Exhibit 110: Data Table on Germany – Year-over-year growth 2022-2027 (%)
o 9.10 Japan – Market size and forecast 2022-2027
o Exhibit 111: Chart on Japan – Market size and forecast 2022-2027 ($ million)
o Exhibit 112: Data Table on Japan – Market size and forecast 2022-2027 ($ million)
o Exhibit 113: Chart on Japan – Year-over-year growth 2022-2027 (%)
o Exhibit 114: Data Table on Japan – Year-over-year growth 2022-2027 (%)
o 9.11 UK – Market size and forecast 2022-2027
o Exhibit 115: Chart on UK – Market size and forecast 2022-2027 ($ million)
o Exhibit 116: Data Table on UK – Market size and forecast 2022-2027 ($ million)
o Exhibit 117: Chart on UK – Year-over-year growth 2022-2027 (%)
o Exhibit 118: Data Table on UK – Year-over-year growth 2022-2027 (%)
o 9.12 Market opportunity By Geographical Landscape
o Exhibit 119: Market opportunity By Geographical Landscape ($ million)
o Exhibit 120: Data Tables on Market opportunity By Geographical Landscape ($ million)
10 Drivers, Challenges, and Trends
o 10.1 Market drivers
o 10.2 Market challenges
o 10.3 Impact of drivers and challenges
o Exhibit 121: Impact of drivers and challenges in 2022 and 2027
o 10.4 Market trends
11 Vendor Landscape
o 11.1 Overview
o 11.2 Vendor landscape
o Exhibit 122: Overview on Criticality of inputs and Factors of differentiation
o 11.3 Landscape disruption
o Exhibit 123: Overview on factors of disruption
o 11.4 Industry risks
o Exhibit 124: Impact of key risks on business
12 Vendor Analysis
o 12.1 Vendors covered
o Exhibit 125: Vendors covered
o 12.2 Market positioning of vendors
o Exhibit 126: Matrix on vendor position and classification
o 12.3 Boehringer Ingelheim International GmbH
o Exhibit 127: Boehringer Ingelheim International GmbH – Overview
o Exhibit 128: Boehringer Ingelheim International GmbH – Business segments
o Exhibit 129: Boehringer Ingelheim International GmbH – Key news
o Exhibit 130: Boehringer Ingelheim International GmbH – Key offerings
o Exhibit 131: Boehringer Ingelheim International GmbH – Segment focus
o 12.4 Cadila Pharmaceuticals Ltd.
o Exhibit 132: Cadila Pharmaceuticals Ltd. – Overview
o Exhibit 133: Cadila Pharmaceuticals Ltd. – Product / Service
o Exhibit 134: Cadila Pharmaceuticals Ltd. – Key offerings
o 12.5 Cipla Ltd.
o Exhibit 135: Cipla Ltd. – Overview
o Exhibit 136: Cipla Ltd. – Business segments
o Exhibit 137: Cipla Ltd. – Key news
o Exhibit 138: Cipla Ltd. – Key offerings
o Exhibit 139: Cipla Ltd. – Segment focus
o 12.6 Fresenius SE and Co. KGaA
o Exhibit 140: Fresenius SE and Co. KGaA – Overview
o Exhibit 141: Fresenius SE and Co. KGaA – Business segments
o Exhibit 142: Fresenius SE and Co. KGaA – Key news
o Exhibit 143: Fresenius SE and Co. KGaA – Key offerings
o Exhibit 144: Fresenius SE and Co. KGaA – Segment focus
o 12.7 GlaxoSmithKline Plc
o Exhibit 145: GlaxoSmithKline Plc – Overview
o Exhibit 146: GlaxoSmithKline Plc – Business segments
o Exhibit 147: GlaxoSmithKline Plc – Key news
o Exhibit 148: GlaxoSmithKline Plc – Key offerings
o Exhibit 149: GlaxoSmithKline Plc – Segment focus
o 12.8 Helsinn Healthcare SA
o Exhibit 150: Helsinn Healthcare SA – Overview
o Exhibit 151: Helsinn Healthcare SA – Product / Service
o Exhibit 152: Helsinn Healthcare SA – Key offerings
o 12.9 Lupin Ltd.
o Exhibit 153: Lupin Ltd. – Overview
o Exhibit 154: Lupin Ltd. – Product / Service
o Exhibit 155: Lupin Ltd. – Key news
o Exhibit 156: Lupin Ltd. – Key offerings
o 12.10 Merck and Co. Inc.
o Exhibit 157: Merck and Co. Inc. – Overview
o Exhibit 158: Merck and Co. Inc. – Business segments
o Exhibit 159: Merck and Co. Inc. – Key news
o Exhibit 160: Merck and Co. Inc. – Key offerings
o Exhibit 161: Merck and Co. Inc. – Segment focus
o 12.11 Novartis AG
o Exhibit 162: Novartis AG – Overview
o Exhibit 163: Novartis AG – Business segments
o Exhibit 164: Novartis AG – Key offerings
o Exhibit 165: Novartis AG – Segment focus
o 12.12 Otsuka Holdings Co. Ltd.
o Exhibit 166: Otsuka Holdings Co. Ltd. – Overview
o Exhibit 167: Otsuka Holdings Co. Ltd. – Business segments
o Exhibit 168: Otsuka Holdings Co. Ltd. – Key offerings
o Exhibit 169: Otsuka Holdings Co. Ltd. – Segment focus
o 12.13 Pfizer Inc.
o Exhibit 170: Pfizer Inc. – Overview
o Exhibit 171: Pfizer Inc. – Product / Service
o Exhibit 172: Pfizer Inc. – Key news
o Exhibit 173: Pfizer Inc. – Key offerings
o 12.14 Sanofi
o Exhibit 174: Sanofi – Overview
o Exhibit 175: Sanofi – Business segments
o Exhibit 176: Sanofi – Key news
o Exhibit 177: Sanofi – Key offerings
o Exhibit 178: Sanofi – Segment focus
o 12.15 Takeda Pharmaceutical Co. Ltd.
o Exhibit 179: Takeda Pharmaceutical Co. Ltd. – Overview
o Exhibit 180: Takeda Pharmaceutical Co. Ltd. – Product / Service
o Exhibit 181: Takeda Pharmaceutical Co. Ltd. – Key news
o Exhibit 182: Takeda Pharmaceutical Co. Ltd. – Key offerings
o 12.16 Teva Pharmaceutical Industries Ltd.
o Exhibit 183: Teva Pharmaceutical Industries Ltd. – Overview
o Exhibit 184: Teva Pharmaceutical Industries Ltd. – Business segments
o Exhibit 185: Teva Pharmaceutical Industries Ltd. – Key news
o Exhibit 186: Teva Pharmaceutical Industries Ltd. – Key offerings
o Exhibit 187: Teva Pharmaceutical Industries Ltd. – Segment focus
o 12.17 Viatris Inc.
o Exhibit 188: Viatris Inc. – Overview
o Exhibit 189: Viatris Inc. – Business segments
o Exhibit 190: Viatris Inc. – Key news
o Exhibit 191: Viatris Inc. – Key offerings
o Exhibit 192: Viatris Inc. – Segment focus
13 Appendix
o 13.1 Scope of the report
o 13.2 Inclusions and exclusions checklist
o Exhibit 193: Inclusions checklist
o Exhibit 194: Exclusions checklist
o 13.3 Currency conversion rates for US$
o Exhibit 195: Currency conversion rates for US$
o 13.4 Research methodology
o Exhibit 196: Research methodology
o Exhibit 197: Validation techniques employed for market sizing
o Exhibit 198: Information sources
o 13.5 List of abbreviations
o Exhibit 199: List of abbreviations

Exhibits:
Exhibits1: Executive Summary – Chart on Market Overview
Exhibits2: Executive Summary – Data Table on Market Overview
Exhibits3: Executive Summary – Chart on Global Market Characteristics
Exhibits4: Executive Summary – Chart on Market By Geographical Landscape
Exhibits5: Executive Summary – Chart on Market Segmentation by Drug Class
Exhibits6: Executive Summary – Chart on Market Segmentation by Application
Exhibits7: Executive Summary – Chart on Incremental Growth
Exhibits8: Executive Summary – Data Table on Incremental Growth
Exhibits9: Executive Summary – Chart on Vendor Market Positioning
Exhibits10: Parent market
Exhibits11: Market Characteristics
Exhibits12: Offerings of vendors included in the market definition
Exhibits13: Market segments
Exhibits14: Chart on Global – Market size and forecast 2022-2027 ($ million)
Exhibits15: Data Table on Global – Market size and forecast 2022-2027 ($ million)
Exhibits16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
Exhibits17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
Exhibits18: Historic Market Size – Data Table on global antiemetic drug market 2017 – 2021 ($ million)
Exhibits19: Historic Market Size – Drug Class Segment 2017 – 2021 ($ million)
Exhibits20: Historic Market Size – Application Segment 2017 – 2021 ($ million)
Exhibits21: Historic Market Size – Geography Segment 2017 – 2021 ($ million)
Exhibits22: Historic Market Size – Country Segment 2017 – 2021 ($ million)
Exhibits23: Five forces analysis – Comparison between 2022 and 2027
Exhibits24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027
Exhibits25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027
Exhibits26: Threat of new entrants – Impact of key factors in 2022 and 2027
Exhibits27: Threat of substitutes – Impact of key factors in 2022 and 2027
Exhibits28: Threat of rivalry – Impact of key factors in 2022 and 2027
Exhibits29: Chart on Market condition – Five forces 2022 and 2027
Exhibits30: Chart on Drug Class – Market share 2022-2027 (%)
Exhibits31: Data Table on Drug Class – Market share 2022-2027 (%)
Exhibits32: Chart on Comparison by Drug Class
Exhibits33: Data Table on Comparison by Drug Class
Exhibits34: Chart on 5-Hydroxytryptamine 3 (5-HT 3) receptor antagonist – Market size and forecast 2022-2027 ($ million)
Exhibits35: Data Table on 5-Hydroxytryptamine 3 (5-HT 3) receptor antagonist – Market size and forecast 2022-2027 ($ million)
Exhibits36: Chart on 5-Hydroxytryptamine 3 (5-HT 3) receptor antagonist – Year-over-year growth 2022-2027 (%)
Exhibits37: Data Table on 5-Hydroxytryptamine 3 (5-HT 3) receptor antagonist – Year-over-year growth 2022-2027 (%)
Exhibits38: Chart on Dopamine antagonist – Market size and forecast 2022-2027 ($ million)
Exhibits39: Data Table on Dopamine antagonist – Market size and forecast 2022-2027 ($ million)
Exhibits40: Chart on Dopamine antagonist – Year-over-year growth 2022-2027 (%)
Exhibits41: Data Table on Dopamine antagonist – Year-over-year growth 2022-2027 (%)
Exhibits42: Chart on Neurokinin-1 (NK 1) receptor antagonist – Market size and forecast 2022-2027 ($ million)
Exhibits43: Data Table on Neurokinin-1 (NK 1) receptor antagonist – Market size and forecast 2022-2027 ($ million)
Exhibits44: Chart on Neurokinin-1 (NK 1) receptor antagonist – Year-over-year growth 2022-2027 (%)
Exhibits45: Data Table on Neurokinin-1 (NK 1) receptor antagonist – Year-over-year growth 2022-2027 (%)
Exhibits46: Chart on Cannabinoid receptor antagonist – Market size and forecast 2022-2027 ($ million)
Exhibits47: Data Table on Cannabinoid receptor antagonist – Market size and forecast 2022-2027 ($ million)
Exhibits48: Chart on Cannabinoid receptor antagonist – Year-over-year growth 2022-2027 (%)
Exhibits49: Data Table on Cannabinoid receptor antagonist – Year-over-year growth 2022-2027 (%)
Exhibits50: Chart on Others – Market size and forecast 2022-2027 ($ million)
Exhibits51: Data Table on Others – Market size and forecast 2022-2027 ($ million)
Exhibits52: Chart on Others – Year-over-year growth 2022-2027 (%)
Exhibits53: Data Table on Others – Year-over-year growth 2022-2027 (%)
Exhibits54: Market opportunity by Drug Class ($ million)
Exhibits55: Data Table on Market opportunity by Drug Class ($ million)
Exhibits56: Chart on Application – Market share 2022-2027 (%)
Exhibits57: Data Table on Application – Market share 2022-2027 (%)
Exhibits58: Chart on Comparison by Application
Exhibits59: Data Table on Comparison by Application
Exhibits60: Chart on Chemotherapy – Market size and forecast 2022-2027 ($ million)
Exhibits61: Data Table on Chemotherapy – Market size and forecast 2022-2027 ($ million)
Exhibits62: Chart on Chemotherapy – Year-over-year growth 2022-2027 (%)
Exhibits63: Data Table on Chemotherapy – Year-over-year growth 2022-2027 (%)
Exhibits64: Chart on Surgery – Market size and forecast 2022-2027 ($ million)
Exhibits65: Data Table on Surgery – Market size and forecast 2022-2027 ($ million)
Exhibits66: Chart on Surgery – Year-over-year growth 2022-2027 (%)
Exhibits67: Data Table on Surgery – Year-over-year growth 2022-2027 (%)
Exhibits68: Chart on Gastroenteritis – Market size and forecast 2022-2027 ($ million)
Exhibits69: Data Table on Gastroenteritis – Market size and forecast 2022-2027 ($ million)
Exhibits70: Chart on Gastroenteritis – Year-over-year growth 2022-2027 (%)
Exhibits71: Data Table on Gastroenteritis – Year-over-year growth 2022-2027 (%)
Exhibits72: Chart on Others – Market size and forecast 2022-2027 ($ million)
Exhibits73: Data Table on Others – Market size and forecast 2022-2027 ($ million)
Exhibits74: Chart on Others – Year-over-year growth 2022-2027 (%)
Exhibits75: Data Table on Others – Year-over-year growth 2022-2027 (%)
Exhibits76: Market opportunity by Application ($ million)
Exhibits77: Data Table on Market opportunity by Application ($ million)
Exhibits78: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Exhibits79: Chart on Market share By Geographical Landscape 2022-2027 (%)
Exhibits80: Data Table on Market share By Geographical Landscape 2022-2027 (%)
Exhibits81: Chart on Geographic comparison
Exhibits82: Data Table on Geographic comparison
Exhibits83: Chart on North America – Market size and forecast 2022-2027 ($ million)
Exhibits84: Data Table on North America – Market size and forecast 2022-2027 ($ million)
Exhibits85: Chart on North America – Year-over-year growth 2022-2027 (%)
Exhibits86: Data Table on North America – Year-over-year growth 2022-2027 (%)
Exhibits87: Chart on Europe – Market size and forecast 2022-2027 ($ million)
Exhibits88: Data Table on Europe – Market size and forecast 2022-2027 ($ million)
Exhibits89: Chart on Europe – Year-over-year growth 2022-2027 (%)
Exhibits90: Data Table on Europe – Year-over-year growth 2022-2027 (%)
Exhibits91: Chart on Asia – Market size and forecast 2022-2027 ($ million)
Exhibits92: Data Table on Asia – Market size and forecast 2022-2027 ($ million)
Exhibits93: Chart on Asia – Year-over-year growth 2022-2027 (%)
Exhibits94: Data Table on Asia – Year-over-year growth 2022-2027 (%)
Exhibits95: Chart on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
Exhibits96: Data Table on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
Exhibits97: Chart on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
Exhibits98: Data Table on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
Exhibits99: Chart on US – Market size and forecast 2022-2027 ($ million)
Exhibits100: Data Table on US – Market size and forecast 2022-2027 ($ million)
Exhibits101: Chart on US – Year-over-year growth 2022-2027 (%)
Exhibits102: Data Table on US – Year-over-year growth 2022-2027 (%)
Exhibits103: Chart on China – Market size and forecast 2022-2027 ($ million)
Exhibits104: Data Table on China – Market size and forecast 2022-2027 ($ million)
Exhibits105: Chart on China – Year-over-year growth 2022-2027 (%)
Exhibits106: Data Table on China – Year-over-year growth 2022-2027 (%)
Exhibits107: Chart on Germany – Market size and forecast 2022-2027 ($ million)
Exhibits108: Data Table on Germany – Market size and forecast 2022-2027 ($ million)
Exhibits109: Chart on Germany – Year-over-year growth 2022-2027 (%)
Exhibits110: Data Table on Germany – Year-over-year growth 2022-2027 (%)
Exhibits111: Chart on Japan – Market size and forecast 2022-2027 ($ million)
Exhibits112: Data Table on Japan – Market size and forecast 2022-2027 ($ million)
Exhibits113: Chart on Japan – Year-over-year growth 2022-2027 (%)
Exhibits114: Data Table on Japan – Year-over-year growth 2022-2027 (%)
Exhibits115: Chart on UK – Market size and forecast 2022-2027 ($ million)
Exhibits116: Data Table on UK – Market size and forecast 2022-2027 ($ million)
Exhibits117: Chart on UK – Year-over-year growth 2022-2027 (%)
Exhibits118: Data Table on UK – Year-over-year growth 2022-2027 (%)
Exhibits119: Market opportunity By Geographical Landscape ($ million)
Exhibits120: Data Tables on Market opportunity By Geographical Landscape ($ million)
Exhibits121: Impact of drivers and challenges in 2022 and 2027
Exhibits122: Overview on Criticality of inputs and Factors of differentiation
Exhibits123: Overview on factors of disruption
Exhibits124: Impact of key risks on business
Exhibits125: Vendors covered
Exhibits126: Matrix on vendor position and classification
Exhibits127: Boehringer Ingelheim International GmbH – Overview
Exhibits128: Boehringer Ingelheim International GmbH – Business segments
Exhibits129: Boehringer Ingelheim International GmbH – Key news
Exhibits130: Boehringer Ingelheim International GmbH – Key offerings
Exhibits131: Boehringer Ingelheim International GmbH – Segment focus
Exhibits132: Cadila Pharmaceuticals Ltd. – Overview
Exhibits133: Cadila Pharmaceuticals Ltd. – Product / Service
Exhibits134: Cadila Pharmaceuticals Ltd. – Key offerings
Exhibits135: Cipla Ltd. – Overview
Exhibits136: Cipla Ltd. – Business segments
Exhibits137: Cipla Ltd. – Key news
Exhibits138: Cipla Ltd. – Key offerings
Exhibits139: Cipla Ltd. – Segment focus
Exhibits140: Fresenius SE and Co. KGaA – Overview
Exhibits141: Fresenius SE and Co. KGaA – Business segments
Exhibits142: Fresenius SE and Co. KGaA – Key news
Exhibits143: Fresenius SE and Co. KGaA – Key offerings
Exhibits144: Fresenius SE and Co. KGaA – Segment focus
Exhibits145: GlaxoSmithKline Plc – Overview
Exhibits146: GlaxoSmithKline Plc – Business segments
Exhibits147: GlaxoSmithKline Plc – Key news
Exhibits148: GlaxoSmithKline Plc – Key offerings
Exhibits149: GlaxoSmithKline Plc – Segment focus
Exhibits150: Helsinn Healthcare SA – Overview
Exhibits151: Helsinn Healthcare SA – Product / Service
Exhibits152: Helsinn Healthcare SA – Key offerings
Exhibits153: Lupin Ltd. – Overview
Exhibits154: Lupin Ltd. – Product / Service
Exhibits155: Lupin Ltd. – Key news
Exhibits156: Lupin Ltd. – Key offerings
Exhibits157: Merck and Co. Inc. – Overview
Exhibits158: Merck and Co. Inc. – Business segments
Exhibits159: Merck and Co. Inc. – Key news
Exhibits160: Merck and Co. Inc. – Key offerings
Exhibits161: Merck and Co. Inc. – Segment focus
Exhibits162: Novartis AG – Overview
Exhibits163: Novartis AG – Business segments
Exhibits164: Novartis AG – Key offerings
Exhibits165: Novartis AG – Segment focus
Exhibits166: Otsuka Holdings Co. Ltd. – Overview
Exhibits167: Otsuka Holdings Co. Ltd. – Business segments
Exhibits168: Otsuka Holdings Co. Ltd. – Key offerings
Exhibits169: Otsuka Holdings Co. Ltd. – Segment focus
Exhibits170: Pfizer Inc. – Overview
Exhibits171: Pfizer Inc. – Product / Service
Exhibits172: Pfizer Inc. – Key news
Exhibits173: Pfizer Inc. – Key offerings
Exhibits174: Sanofi – Overview
Exhibits175: Sanofi – Business segments
Exhibits176: Sanofi – Key news
Exhibits177: Sanofi – Key offerings
Exhibits178: Sanofi – Segment focus
Exhibits179: Takeda Pharmaceutical Co. Ltd. – Overview
Exhibits180: Takeda Pharmaceutical Co. Ltd. – Product / Service
Exhibits181: Takeda Pharmaceutical Co. Ltd. – Key news
Exhibits182: Takeda Pharmaceutical Co. Ltd. – Key offerings
Exhibits183: Teva Pharmaceutical Industries Ltd. – Overview
Exhibits184: Teva Pharmaceutical Industries Ltd. – Business segments
Exhibits185: Teva Pharmaceutical Industries Ltd. – Key news
Exhibits186: Teva Pharmaceutical Industries Ltd. – Key offerings
Exhibits187: Teva Pharmaceutical Industries Ltd. – Segment focus
Exhibits188: Viatris Inc. – Overview
Exhibits189: Viatris Inc. – Business segments
Exhibits190: Viatris Inc. – Key news
Exhibits191: Viatris Inc. – Key offerings
Exhibits192: Viatris Inc. – Segment focus
Exhibits193: Inclusions checklist
Exhibits194: Exclusions checklist
Exhibits195: Currency conversion rates for US$
Exhibits196: Research methodology
Exhibits197: Validation techniques employed for market sizing
Exhibits198: Information sources
Exhibits199: List of abbreviations

※본 조사보고서 [글로벌 항구토제 시장 2023-2027 : 화학요법, 외과적 치료, 위장염, 기타] (코드 : IRTNTR75902-23) 판매에 관한 면책사항을 반드시 확인하세요.
※본 조사보고서 [글로벌 항구토제 시장 2023-2027 : 화학요법, 외과적 치료, 위장염, 기타] 에 대해서 E메일 문의는 여기를 클릭하세요.
※당 사이트에 없는 보고서도 취급 가능한 경우가 많으니 문의 주세요!